Literature DB >> 9098855

Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge.

X Ye1, M B Robinson, C Pabin, T Quinn, A Jawad, J M Wilson, M L Batshaw.   

Abstract

The purpose of this study was to determine the time of onset, duration, and the efficacy of in vivo gene transfer in protecting the ornithine transcarbamylase deficient spf/Y mouse from an acute ammonium challenge. The animals were challenged with ammonia (10 mmol/kg NH4Cl) 1, 2, 7, 14, or 28 d after the administration of a recombinant adenoviral construct deleted in E1 and with a temperature sensitive mutation in E2. Although there was no protection with the control LacZ virus, the ornithine transcarbamylase (OTC)-containing vector provided partial protection from both behavioral symptoms (ataxia, seizures, and abnormal response to sound) and biochemical abnormalities (ammonium, aspartate, alanine, and glutamine) within 24 h and complete protection by 48 h. Mortality was also decreased. Animals receiving the vector 7 and 14 d before the ammonium load were also protected, whereas those treated 28 d before the challenge were not. OTC enzyme activity in liver of untreated spf/Y mice was 5% of control C3H mice. After gene transfer, activity was increased to near control levels through 14 d but had returned to baseline by 28 d. These studies indicate that adenovirus-mediated gene transfer confers a metabolic benefit within 24 h of administration and provides protection against an acute metabolic insult for at least 2 wk.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098855     DOI: 10.1203/00006450-199704000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  12 in total

1.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 2.  Helper-dependent adenoviral vectors in experimental gene therapy.

Authors:  Alicja Józkowicz; Józef Dulak
Journal:  Acta Biochim Pol       Date:  2005-08-04       Impact factor: 2.149

3.  Enhancement of hepatic autophagy increases ureagenesis and protects against hyperammonemia.

Authors:  Leandro R Soria; Gabriella Allegri; Dominique Melck; Nunzia Pastore; Patrizia Annunziata; Debora Paris; Elena Polishchuk; Edoardo Nusco; Beat Thöny; Andrea Motta; Johannes Häberle; Andrea Ballabio; Nicola Brunetti-Pierri
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

4.  Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.

Authors:  Lili Wang; Hiroki Morizono; Jianping Lin; Peter Bell; David Jones; Deirdre McMenamin; Hongwei Yu; Mark L Batshaw; James M Wilson
Journal:  Mol Genet Metab       Date:  2011-11-07       Impact factor: 4.797

5.  A novel biochemically salvageable animal model of hyperammonemia devoid of N-acetylglutamate synthase.

Authors:  Emilee Senkevitch; Juan Cabrera-Luque; Hiroki Morizono; Ljubica Caldovic; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2012-03-17       Impact factor: 4.797

6.  SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy.

Authors:  Alberto Bergareche; Marcin Bednarz; Elena Sánchez; Catharine E Krebs; Javier Ruiz-Martinez; Patricia De La Riva; Vladimir Makarov; Ana Gorostidi; Karin Jurkat-Rott; Jose Felix Marti-Masso; Coro Paisán-Ruiz
Journal:  Hum Mol Genet       Date:  2015-10-01       Impact factor: 6.150

7.  Evaluation of gene therapy for citrullinaemia using murine and bovine models.

Authors:  G Patejunas; B Lee; J A Dennis; P J Healy; P J Reeds; H Yu; M Frazer; B Mull; A W Warman; A L Beaudet; W E O'Brien
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

8.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  Overexpression of the cholesterol-binding protein MLN64 induces liver damage in the mouse.

Authors:  Juan-Enrique Tichauer; Maria-Gabriela Morales; Ludwig Amigo; Leopoldo Galdames; Andres Klein; Veronica Quinones; Carla Ferrada; Alejandra-R Alvarez; Marie-Christine Rio; Juan-Francisco Miquel; Attilio Rigotti; Silvana Zanlungo
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

10.  AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse.

Authors:  E K Lee; C Hu; R Bhargava; R Ponnusamy; H Park; S Novicoff; N Rozengurt; B Marescau; P De Deyn; D Stout; L Schlichting; W W Grody; S D Cederbaum; G S Lipshutz
Journal:  Gene Ther       Date:  2013-02-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.